NZYM B Novozymes A/S Class B

Invitation to Novozymes' annual shareholders' meeting 2023

Invitation to Novozymes' annual shareholders' meeting 2023

To the shareholders of Novozymes A/S

The Board of Directors is pleased to invite you to the company's annual shareholders' meeting on Thursday March 2, 2023 at 4:00 pm CET at Ballerup Super Arena

Please read the invitation in PDF



Til Novozymes A/S' aktionærer

Betyrelsen har hermed fornøjelsen af at invitere dig til selskabets ordinære generalforsamling torsdag den 2. marts 2023 kl. 16.00 i Ballerup Super Arena

Læs venligst den fulde invitation i PDF format

Attachments



EN
03/02/2023

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis delivered strong organic sales growth of 7% in 2025

Novonesis delivered strong organic sales growth of 7% in 2025 COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.  Ester Baiget, President & CEO:  “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a...

11h / 8m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Incentive programs for the Executive Leadership Team, the Senior Leade...

Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees Please read the full announcement in PDF Attachment

11h / 10m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis' Annual Report 2025

Novonesis' Annual Report 2025 Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO:”In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a pure biosolutions player, Novonesis uniquely combines deep understanding of ...

11h / 22m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

November 21, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch